Ratings by Leerink (Asthika Goonewardene)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 10/5/2026 | Zentalis Pharmaceuticals | ZNTL | New Coverage | Outperform (N/A) |
2.52 (2.21) |
-12.3% | Details | |
| 10/5/2026 | Exelixis | EXEL | New Coverage | Market Perform (N/A) |
58.39 (64.53) |
10.52% | Details | |
| 10/5/2026 | Genmab A/S | GMAB | New Coverage | Outperform (N/A) |
34.75 (43.79) |
26.01% | Details | |
| 10/5/2026 | ORIC Pharmaceuticals | ORIC | New Coverage | Outperform (N/A) |
12.21 (13.17) |
7.86% | Details | |
| 7/21/2026 | Whitehawk Therapeutics | WHWK | New Coverage | Outperform (N/A) |
3.79 (3.21) |
-15.3% | Details | |
| 7/21/2026 | Molecular Partners | MOLN | New Coverage | Outperform (N/A) |
4.00 (3.67) |
-8.25% | Details | |
| 7/21/2026 | Kura Oncology | KURA | New Coverage | Outperform (N/A) |
10.68 (9.61) |
-10.02% | Details | |
| 7/21/2026 | Compass Therapeutics | CMPX | New Coverage | Outperform (N/A) |
2.02 (0.76) |
-62.38% | Details | |
| 7/21/2026 | Aktis Oncology | AKTS | New Coverage | Outperform (N/A) |
23.96 (15.73) |
-34.35% | Details |
